Journal of Clinical Oncology
Articles in this Issue
First next-generation sequencing (NGS) testing at the end of life in patients with metastatic prostate cancer.
90 Background: Poly(ADP) ribose polymerase inhibitors and pembrolizumab are approved for patients with metastatic prostate cancer (mPC) with susceptible g...
Hydroxychloroquine effects on tumor suppressor PAR-4 levels in patients with oligometastatic prostate cancer: Results from a phase-2 trial.
233 Background: In oligometastatic prostate cancer (OMPC), delaying time to initiation of androgen deprivation therapy (AD...
Severity of bleomycin-induced lung toxicity in Indian patients with intermediate and poor-risk non-seminomatous germ cell tumors (NSGCT): A clinical perspective.
635 Background: Bleomycin, etoposide and cisplatin (BEP) chemotherapy is the standard of care in advanced NSGCT due to its extremely high efficacy. The in...
Long-term outcomes of neoadjuvant chemotherapy (NAC) before bladder-sparing chemoradiotherapy (CRT) for patients with nonmetastatic muscle-invasive bladder cancer (MIBC).
819 Background: Neoadjuvant cisplatin-based combination chemotherapy followed by concurrent chemoradiation is an emerging approach in carefully selected M...
Metastasis-directed radiotherapy in oligometastatic bladder and upper tract cancer: A single institution retrospective experience.
799 Background: Metastasis-directed therapy (MDT) for oligometastatic cancer is a concept utilized for prostate and kidney cancer. Clinical research in MD...
Clinicopathological features and prognosis of MED15-TFE3 rearrangement renal cell carcinoma: An updated report.
492 Background: TFE3-rearranged renal cell carcinoma (rRCC) is uncommon, and demonstrates unique heterogenous morphological features and distinct immune c...
Association of high ctDNA tumor fraction (TF) and detection of clinically significant copy number (CN) losses in liquid biopsies (LBx) from patients with advanced prostate cancer (PCa).
53 Background: Detection of somatic genomic alterations (GA) in LBx is dependent upon the amount of tumor DNA shed, inferred by ctDNA TF. Many clinically...
Complications after transurethral resection of bladder tumor: Findings from the 2022 ACS NSQIP database.
742 Background: Transurethral resection of bladder tumor (TURBT) is a widely utilized procedure for the diagnosis and trea...
Racial differences in active surveillance intensity and overtreatment in men with prostate cancer.
316 Background: Marginalized communities in cancer care are often characterized by lower healthcare utilization. In prostate cancer, however, utilization...
A phase 2 study of cabozantinib and nivolumab in metastatic castration resistant prostate cancer (CANOPY).
TPS302 Background: Advanced metastatic-castration-resistant prostate cancer (mCRPC) remains a lethal disease with limited treatment options. Cabozantinib...
The estrogen response pathway as a putative predictive biomarker of neoadjuvant pembrolizumab benefit in patients with muscle-invasive bladder carcinoma (MIBC).
843 Background: Sex-specific differences in incidence, stage, and prognosis of have raised interest in the role of sex steroid hormones in pathogenesis an...
Mechanism of action and translation to the clinic of detalimogene voraplasmid (EG-70): A novel, investigational, non-viral immunotherapy for non-muscle-invasive bladder cancer (NMIBC).
826 Background: Detalimogene voraplasmid (EG-70) is a novel, investigational, non-integrating, non-viral gene therapy designed to elicit local stimulation...
Heterogeneity in subgroup reporting across clinical trials assessing systemic therapies in metastatic castration resistant prostate cancer: A report from a living systematic review.
270 Background: Inconsistent reporting of subgroup data across clinical trials makes interpretation and application of the evidence from trials challengin...
Clinicopathological variations between early and late recurrence in bladder cancer post-radical cystectomy.
874 Background: Over 50% of patients diagnosed with muscle-invasive bladder cancer are estimated to experience urothelial cell carcinoma (UCC) recurrence...
Association between neutrophil and tumor-infiltrating lymphocyte count and bladder cancer stage and treatment response in BCG-treated mice models.
823 Background: Although Bacillus Calmette-Guérin (BCG) is widely used to treat bladder cancer, its mechanism is still not fully understood. Tumor-infiltr...
The impact of social vulnerability on perceived health in individuals with bladder cancer.
678 Background: Bladder cancer is the sixth most common malignancy in the United States. Social determinants of health (SDOH) have been increasingly recog...
CHAPTER-Platform-201: Phase 2 trial of pimitespib plus enzalutamide for patients with metastatic castration-resistant prostate cancer.
TPS296 Background: Metastatic castration-resistant prostate cancer (mCRPC) patients (pts), especially those who experience disease progression while on an...
Beyond survival: Understanding the social dimensions of prostate cancer.
28 Background: Prostate cancer carries one of the highest burdens of racial disparities in outcomes in oncology. Understanding social determinants of heal...
Multicenter analysis of high-dose chemotherapy (HDCT) regimens for recurrent germ cell tumors (GCTs).
631 Background: HDCT is an established salvage treatment for patients (pts) with recurrent germ cell tumors (GCTs). However, comparative analyses between...
Prospective observational study in Japanese patients with metastatic castration-sensitive prostate cancer (mCSPC) with or without intraductal carcinoma of the prostate (IDC-P).
87 Background: Intraductal carcinoma of the prostate (IDC-P) is a high-grade, high-volume, invasive form of prostate cancer (PCa) associated with poor cli...
Evaluating cost-effectiveness in the evolving treatment landscape for metastatic urothelial carcinoma.
695 Background: Metastatic urothelial carcinoma (mUCa) is the most expensive cancer to treat on a per-patient basis, largely due to the need for frequent...
AI-driven prediction of prostate cancer risk: A comparative analysis with C the Signs in the Mayo Clinic data platform.
371 Background: Prostate cancer is the most common malignancy in men globally and remains among the top five leading causes of cancer-related deaths. Emer...
Addition of darolutamide to first line treatment of metastatic castration-resistant prostate cancer (mCRPC): A randomized open label phase II trial (SAKK 08/23).
TPS280 Background: The implementation of androgen-receptor pathway inhibitors (ARPI) +/- docetaxel (doce) in addition to androgen deprivation therapy (ADT...
The prognostic significance of prostate-specific antigen dynamics during abiraterone therapy in patients with high-risk metastatic hormone-sensitive prostate cancer.
78 Background: The depth reduction in prostate-specific antigen (PSA) levels serves as a prognostic indicator for patients with high-risk metastatic hormo...
Chronic obstructive pulmonary disease mortality risk in renal cell carcinoma: A population-based study from 1992-2021.
450 Background: Renal Cell Carcinoma (RCC) is one of the most common malignancies in the United States, with about 82000 new cases and 15000 deaths each y...